TDMS Study 05109-14 Pathology Tables
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
FINAL #1/MICE
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 05/31/01
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 7 6 4 7
Moribund Sacrifice 8 10 5 10
Accidently Killed 1
Survivors
Terminal Sacrifice 34 34 41 32
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (50) (50) (50)
Serosa, Inflammation, Chronic 1 (2%)
Intestine Small, Duodenum (50) (50) (50) (50)
Epithelium, Necrosis 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50)
Diverticulum 1 (2%)
Ulcer 1 (2%)
Peyer's Patch, Hyperplasia 1 (2%)
Peyer's Patch, Inflammation, Suppurative 1 (2%)
Serosa, Inflammation, Granulomatous 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis, Focal 1 (2%)
Basophilic Focus 4 (8%) 3 (6%) 3 (6%)
Clear Cell Focus 4 (8%) 3 (6%) 3 (6%) 5 (10%)
Eosinophilic Focus 16 (32%) 22 (44%) 28 (56%) 32 (64%)
Fibrosis, Focal 1 (2%)
Hematopoietic Cell Proliferation 4 (8%) 3 (6%) 3 (6%) 4 (8%)
Hepatodiaphragmatic Nodule 2 (4%)
Infiltration Cellular, Lymphoid 26 (52%) 30 (60%) 36 (72%) 20 (40%)
Inflammation, Chronic 14 (28%) 27 (54%) 22 (44%) 15 (30%)
Mixed Cell Focus 5 (10%) 8 (16%) 14 (28%) 11 (22%)
Necrosis, Focal 5 (10%) 1 (2%) 3 (6%)
Vacuolization Cytoplasmic, Focal 8 (16%) 1 (2%) 6 (12%) 6 (12%)
Centrilobular, Cytomegaly, Diffuse 1 (2%)
Centrilobular, Necrosis 1 (2%) 1 (2%)
Mesentery (11) (6) (4) (9)
Inflammation, Chronic 1 (9%)
Fat, Necrosis 10 (91%) 6 (100%) 3 (75%) 9 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Lymphatic, Angiectasis 1 (9%)
Oral Mucosa (26) (26) (31) (31)
Inflammation, Chronic 26 (100%) 26 (100%) 31 (100%) 31 (100%)
Pancreas (50) (50) (50) (50)
Acinus, Atrophy 1 (2%) 3 (6%) 1 (2%)
Acinus, Hyperplasia 1 (2%)
Duct, Cyst 1 (2%) 2 (4%) 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Ulcer 1 (2%) 2 (4%)
Epithelium, Cyst 1 (2%)
Epithelium, Hyperplasia, Focal 1 (2%) 1 (2%)
Epithelium, Mineralization 1 (2%)
Stomach, Glandular (50) (50) (50) (50)
Inflammation, Acute 1 (2%)
Ulcer 1 (2%) 1 (2%)
Epithelium, Cyst 1 (2%) 1 (2%)
Epithelium, Hyperplasia, Focal 1 (2%) 1 (2%) 1 (2%)
Serosa, Inflammation, Chronic 1 (2%)
Tooth (1)
Inflammation, Chronic 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (50)
Aorta, Inflammation, Chronic 2 (4%)
Aorta, Mineralization 1 (2%) 2 (4%)
Heart (50) (50) (50) (50)
Artery, Inflammation, Chronic 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Atrium, Thrombosis 2 (4%)
Myocardium, Degeneration 4 (8%) 1 (2%)
Myocardium, Inflammation, Acute 1 (2%)
Myocardium, Inflammation, Chronic 1 (2%)
Myocardium, Mineralization 1 (2%) 2 (4%)
Myocardium, Necrosis 1 (2%)
Pericardium, Inflammation, Chronic 1 (2%)
Valve, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Adrenal Cortex (50) (50) (50) (50)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Focal 1 (2%) 1 (2%)
Hypertrophy, Focal 2 (4%) 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Subcapsular, Hyperplasia 49 (98%) 49 (98%) 50 (100%) 50 (100%)
Adrenal Medulla (49) (50) (50) (50)
Hyperplasia, Focal 1 (2%) 1 (2%)
Infiltration Cellular, Histiocyte 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Hyperplasia 25 (50%) 18 (36%) 20 (40%) 18 (36%)
Parathyroid Gland (39) (41) (45) (46)
Cyst 1 (2%)
Pituitary Gland (50) (50) (50) (50)
Angiectasis 1 (2%)
Pars Distalis, Hyperplasia 11 (22%) 3 (6%) 9 (18%) 12 (24%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Inflammation, Granulomatous 1 (2%) 1 (2%)
C-Cell, Hyperplasia 2 (4%)
Follicle, Cyst 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Follicular Cell, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (49) (49) (49)
Cyst 2 (4%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Ovary (50) (50) (50) (50)
Angiectasis 2 (4%) 2 (4%)
Cyst 27 (54%) 22 (44%) 21 (42%) 25 (50%)
Mineralization 1 (2%)
Thrombosis 1 (2%) 3 (6%) 1 (2%)
Uterus (50) (50) (50) (50)
Angiectasis 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Thrombosis 1 (2%) 1 (2%)
Endometrium, Hyperplasia, Cystic 49 (98%) 48 (96%) 47 (94%) 47 (94%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Fibrosis 1 (2%)
Myeloid Cell, Hyperplasia 1 (2%)
Lymph Node (6) (7) (4) (6)
Deep Cervical, Hyperplasia, Lymphoid 1 (14%)
Iliac, Hyperplasia, Lymphoid 1 (14%) 1 (25%)
Lumbar, Hyperplasia, Lymphoid 1 (17%) 1 (25%)
Lumbar, Inflammation, Acute 1 (17%)
Mediastinal, Hyperplasia, Lymphoid 1 (17%) 1 (14%) 2 (33%)
Renal, Hyperplasia, Lymphoid 1 (17%)
Lymph Node, Mandibular (49) (50) (50) (50)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 2 (4%)
Lymph Node, Mesenteric (50) (49) (48) (48)
Hyperplasia, Histiocytic 1 (2%)
Spleen (50) (50) (49) (50)
Atrophy 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 32 (64%) 24 (48%) 30 (61%) 33 (66%)
Hyperplasia, Lymphoid 1 (2%)
Thymus (49) (49) (49) (49)
Atrophy 13 (27%) 17 (35%) 19 (39%) 16 (33%)
Hyperplasia, Focal 1 (2%)
Hyperplasia, Histiocytic 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Duct, Dilatation 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Epidermis, Hyperkeratosis 1 (2%)
Epidermis, Hyperplasia 1 (2%)
Epidermis, Inflammation, Suppurative 1 (2%)
Epidermis, Ulcer 1 (2%)
Site of Application - Epidermis,
Hyperkeratosis 3 (6%)
Site of Application - Epidermis, Hyperplasia 14 (28%) 50 (100%) 46 (92%) 50 (100%)
Site of Application - Epidermis,
Inflammation, Suppurative 1 (2%) 2 (4%) 20 (40%) 32 (64%)
Site of Application - Epidermis, Ulcer 1 (2%) 1 (2%) 6 (12%) 17 (34%)
Subcutaneous Tissue, Edema 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Subcutaneous Tissue, Fibrosis 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic 1 (2%)
Subcutaneous Tissue, Necrosis 1 (2%)
Subcutaneous Tissue, Site of Application -
Dermis, Inflammation, Chronic 4 (8%) 27 (54%) 31 (62%) 44 (88%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosis 7 (14%) 6 (12%) 13 (26%) 10 (20%)
Fracture 1 (2%)
Hyperostosis 1 (2%)
Cranium, Callus 1 (2%)
Femur, Hyperostosis 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Cyst Epithelial Inclusion 1 (2%)
Hydrocephalus 1 (2%)
Artery, Inflammation, Chronic 1 (2%)
Artery, Meninges, Inflammation, Chronic 1 (2%)
Hypothalamus, Compression 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 2 (4%) 3 (6%) 1 (2%)
Inflammation, Granulomatous 1 (2%)
Mineralization 2 (4%)
Alveolar Epithelium, Hyperplasia, Focal 1 (2%) 1 (2%)
Bronchus, Hyperplasia, Focal 1 (2%)
Bronchus, Hyperplasia, Lymphoid 1 (2%)
Mediastinum, Inflammation, Chronic 1 (2%)
Serosa, Inflammation, Chronic 1 (2%)
Nose (50) (50) (50) (50)
Inflammation, Chronic 1 (2%)
Sinus, Inflammation, Suppurative 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (50) (50) (50)
Degeneration 1 (2%)
Inflammation, Chronic 1 (2%)
Harderian Gland (49) (50) (50) (50)
Hyperplasia 4 (8%) 3 (6%) 4 (8%) 5 (10%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hydronephrosis 1 (2%)
Infarct 1 (2%) 5 (10%) 3 (6%) 3 (6%)
Metaplasia, Osseous 1 (2%) 3 (6%)
Nephropathy 24 (48%) 18 (36%) 23 (46%) 20 (40%)
Glomerulus, Amyloid Deposition 2 (4%)
Glomerulus, Cyst 1 (2%)
Papilla, Necrosis 1 (2%) 1 (2%) 1 (2%)
Papilla, Renal Tubule, Atrophy 1 (2%)
Pelvis, Inflammation, Granulomatous 1 (2%)
Renal Tubule, Cyst 1 (2%)
Renal Tubule, Cytoplasmic Alteration 1 (2%)
Renal Tubule, Mineralization 1 (2%)
Urinary Bladder (50) (50) (49) (49)
Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 2 6 8
Natural Death 8 5 10 2
Survivors
Terminal Sacrifice 37 43 34 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (48) (49) (50) (47)
Necrosis 1 (2%)
Intestine Large, Colon (50) (50) (50) (50)
Inflammation, Chronic 1 (2%)
Goblet Cell, Hyperplasia 1 (2%)
Intestine Large, Cecum (50) (50) (50) (50)
Hemorrhage 1 (2%)
Intestine Small, Duodenum (50) (50) (50) (50)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50)
Diverticulum 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Serosa, Inflammation, Granulomatous 1 (2%)
Intestine Small, Ileum (50) (50) (50) (50)
Muscularis, Infiltration Cellular,
Mononuclear Cell 1 (2%)
Liver (50) (50) (50) (50)
Basophilic Focus 2 (4%) 6 (12%) 3 (6%) 2 (4%)
Clear Cell Focus 19 (38%) 23 (46%) 14 (28%) 11 (22%)
Eosinophilic Focus 9 (18%) 20 (40%) 31 (62%) 30 (60%)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 3 (6%) 4 (8%) 1 (2%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%) 1 (2%)
Infiltration Cellular, Lymphoid 3 (6%) 2 (4%) 2 (4%) 3 (6%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 9 (18%) 14 (28%) 10 (20%) 11 (22%)
Mixed Cell Focus 13 (26%) 11 (22%) 15 (30%) 8 (16%)
Necrosis, Focal 4 (8%) 3 (6%) 7 (14%) 6 (12%)
Vacuolization Cytoplasmic, Focal 2 (4%) 1 (2%) 3 (6%) 5 (10%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Centrilobular, Necrosis 1 (2%) 1 (2%)
Mesentery (3) (3) (5) (7)
Inflammation, Granulomatous 1 (20%)
Artery, Inflammation, Chronic 1 (14%)
Fat, Necrosis 3 (100%) 3 (100%) 4 (80%) 5 (71%)
Oral Mucosa (31) (26) (35) (30)
Inflammation, Chronic 31 (100%) 26 (100%) 35 (100%) 30 (100%)
Pancreas (50) (50) (50) (50)
Acinus, Atrophy 1 (2%)
Duct, Cyst 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Inflammation, Suppurative 1 (2%)
Ulcer 1 (2%) 1 (2%)
Epithelium, Cyst 1 (2%)
Epithelium, Hyperplasia, Focal 3 (6%) 3 (6%) 2 (4%)
Stomach, Glandular (50) (50) (50) (50)
Hyperplasia, Lymphoid 1 (2%)
Ulcer 2 (4%)
Epithelium, Hyperplasia, Focal 1 (2%)
Glands, Ectasia 1 (2%)
Tooth (19) (18) (14) (13)
Malformation 19 (100%) 18 (100%) 14 (100%) 13 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (50)
Aorta, Inflammation, Chronic 1 (2%)
Aorta, Mineralization 1 (2%)
Pulmonary Vein, Thrombosis 1 (2%)
Heart (50) (50) (50) (50)
Infiltration Cellular, Mononuclear Cell 3 (6%) 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 2 (4%)
Artery, Inflammation, Chronic 1 (2%) 3 (6%)
Atrium, Thrombosis 1 (2%) 1 (2%)
Coronary Artery, Inflammation, Chronic 1 (2%)
Myocardium, Degeneration 1 (2%)
Myocardium, Mineralization 1 (2%) 1 (2%) 2 (4%)
Valve, Inflammation, Chronic 1 (2%)
Ventricle, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Hyperplasia, Focal 8 (16%) 4 (8%) 3 (6%) 1 (2%)
Hypertrophy, Focal 16 (32%) 21 (42%) 10 (20%) 10 (20%)
Necrosis 1 (2%)
Subcapsular, Hyperplasia 39 (78%) 45 (90%) 40 (80%) 40 (80%)
Zona Glomerulosa, Hyperplasia 2 (4%) 3 (6%) 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Hyperplasia, Focal 2 (4%)
Necrosis 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Hyperplasia 45 (90%) 43 (86%) 43 (86%) 32 (64%)
Pituitary Gland (50) (49) (49) (50)
Pars Distalis, Hyperplasia 1 (2%) 2 (4%) 1 (2%)
Pars Intermedia, Hyperplasia 1 (2%) 3 (6%)
Thyroid Gland (50) (50) (49) (50)
Follicle, Cyst 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1) (1)
Cyst 1 (100%)
Epididymis (50) (50) (50) (50)
Granuloma Sperm 1 (2%) 1 (2%) 2 (4%)
Inflammation, Chronic 1 (2%)
Preputial Gland (50) (50) (50) (50)
Atrophy 1 (2%)
Cyst 10 (20%) 14 (28%) 11 (22%) 15 (30%)
Inflammation, Chronic 1 (2%) 2 (4%)
Inflammation, Suppurative 1 (2%) 3 (6%)
Prostate (50) (50) (50) (50)
Hyperplasia 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Atrophy 1 (2%)
Hyperplasia 1 (2%) 2 (4%) 2 (4%)
Testes (50) (50) (50) (50)
Inflammation, Granulomatous 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Germinal Epithelium, Atrophy 4 (8%) 2 (4%) 1 (2%) 2 (4%)
Germinal Epithelium, Mineralization 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mesenteric (50) (48) (48) (50)
Congestion 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Spleen (49) (50) (50) (50)
Atrophy 4 (8%) 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 14 (29%) 20 (40%) 17 (34%) 19 (38%)
Lymphoid Follicle, Hematopoietic Cell
Proliferation 1 (2%) 1 (2%)
Red Pulp, Infiltration Cellular, Mononuclear
Cell 1 (2%)
Thymus (48) (47) (48) (48)
Atrophy 38 (79%) 37 (79%) 37 (77%) 38 (79%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Dermis, Edema 1 (2%)
Epidermis, Hyperkeratosis 1 (2%)
Epidermis, Ulcer 1 (2%)
Site of Application - Epidermis,
Hyperkeratosis 3 (6%)
Site of Application - Epidermis, Hyperplasia 5 (10%) 44 (88%) 45 (90%) 49 (98%)
Site of Application - Epidermis,
Inflammation, Suppurative 1 (2%) 11 (22%) 33 (66%) 42 (84%)
Site of Application - Epidermis, Ulcer 3 (6%) 20 (40%) 47 (94%)
Subcutaneous Tissue, Site of Application -
Dermis, Inflammation, Chronic 1 (2%) 15 (30%) 40 (80%) 49 (98%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosis 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression 1 (2%)
Spinal Cord (1)
Necrosis 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Infiltration Cellular, Lymphoid 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
Inflammation, Granulomatous 2 (4%)
Alveolar Epithelium, Hyperplasia, Focal 2 (4%) 2 (4%) 1 (2%) 2 (4%)
Bronchus, Hyperplasia, Focal 1 (2%)
Perivascular, Infiltration Cellular, Lymphoid 1 (2%)
Vein, Thrombosis 1 (2%)
Nose (50) (50) (50) (50)
Inflammation, Suppurative 2 (4%) 1 (2%)
Polyp, Inflammatory 1 (2%)
Respiratory Epithelium, Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (50)
Degeneration 1 (2%)
Cornea, Inflammation, Acute 1 (2%)
Retrobulbar, Inflammation, Suppurative 1 (2%)
Harderian Gland (50) (50) (49) (50)
Hyperplasia 3 (6%) 5 (10%) 6 (12%) 7 (14%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hydronephrosis 1 (2%)
Infarct 2 (4%) 3 (6%) 2 (4%) 4 (8%)
Inflammation, Acute 2 (4%)
Metaplasia, Osseous 1 (2%) 4 (8%) 2 (4%) 2 (4%)
Nephropathy 39 (78%) 42 (84%) 37 (74%) 40 (80%)
Artery, Thrombosis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TRIETHANOLAMINE Date: 06/06/02
Route: SKIN APPLICATION Time: 08:29:26
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Capsule, Inflammation, Chronic 1 (2%)
Glomerulus, Cyst 2 (4%) 2 (4%)
Papilla, Necrosis 1 (2%)
Renal Tubule, Cyst 4 (8%) 2 (4%) 4 (8%)
Renal Tubule, Hyperplasia 1 (2%) 1 (2%) 2 (4%)
Urinary Bladder (50) (50) (50) (50)
Cyst 1 (2%)
Inflammation, Acute 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------